Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer.

Chmielecki J, Pao W
Clin Cancer Res. 2010 16 (22): 5371-3

PMID: 21062927 · DOI:10.1158/1078-0432.CCR-10-2405

In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine.

©2010 AACR.

MeSH Terms (9)

Antineoplastic Agents Disease Progression Drug Resistance, Neoplasm ErbB Receptors Humans Lung Neoplasms Molecular Targeted Therapy Mutation Protein Kinase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: